Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE: Repotrectinib in Pediatric and Young Adult ALK/ROS1/NTRK+ Tumors
2023-506464-14-00Phase 2Authorised
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of repotrectinib in Nonhematologic neoplasms, solid tumor, central nervous system primary tumor and 1 more, sponsored by Turning Point Therapeutics, Inc. Primary endpoint: Overall response rate (ORR) as determined by blinded independent central review (BICR). Planned start Jun 2023; status: authorised.
02
Drugs
repotrectinib
03
Conditions
Nonhematologic neoplasmssolid tumorcentral nervous system primary tumorneuroblastoma
Beyond the preview
Go deeper on 2023-506464-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506464-14-00.